The European Medicines Agency distributed the September/October newsletter which reports information about new drug approvals (Covid-19 vaccines, antivirals, cancer, cardiovascular, dermatology, diabetes, gynecology & obstetrics, hematology, HIV, immune system, metabolic disorders, nephrology, nervous system, ophthalmology, respiratory system, rheumatology).
It also reports on the scientific activities of the committees and working parties. There are also posted two draft guidelines for the development and manufacture of synthetic peptides and oligonucleotides. These guidelines are open for consultation until December 20, 2022.
Continue reading here.
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
